Frazier Life Sciences Management L.P. Boosts Holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO)

Frazier Life Sciences Management L.P. boosted its position in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 1.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,800,457 shares of the company's stock after buying an additional 40,000 shares during the period. BridgeBio Pharma makes up 4.3% of Frazier Life Sciences Management L.P.'s holdings, making the stock its 9th biggest holding. Frazier Life Sciences Management L.P. owned about 2.01% of BridgeBio Pharma worth $104,285,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of the company. Capital Research Global Investors boosted its stake in BridgeBio Pharma by 34.9% during the fourth quarter. Capital Research Global Investors now owns 3,526,747 shares of the company's stock worth $96,774,000 after acquiring an additional 912,439 shares in the last quarter. Teacher Retirement System of Texas raised its holdings in shares of BridgeBio Pharma by 28.6% during the fourth quarter. Teacher Retirement System of Texas now owns 36,208 shares of the company's stock valued at $994,000 after purchasing an additional 8,048 shares during the period. Vanguard Group Inc. boosted its position in shares of BridgeBio Pharma by 6.2% during the 4th quarter. Vanguard Group Inc. now owns 15,077,915 shares of the company's stock worth $413,738,000 after purchasing an additional 879,059 shares in the last quarter. Legal & General Group Plc grew its stake in shares of BridgeBio Pharma by 2.8% in the 4th quarter. Legal & General Group Plc now owns 134,038 shares of the company's stock valued at $3,678,000 after buying an additional 3,706 shares during the period. Finally, American Century Companies Inc. increased its position in BridgeBio Pharma by 9.6% in the 4th quarter. American Century Companies Inc. now owns 1,015,728 shares of the company's stock valued at $27,872,000 after buying an additional 88,882 shares in the last quarter. Institutional investors own 99.85% of the company's stock.

Insider Transactions at BridgeBio Pharma

In other BridgeBio Pharma news, Director Andrew Lo sold 100,000 shares of the business's stock in a transaction dated Friday, May 2nd. The shares were sold at an average price of $38.50, for a total value of $3,850,000.00. Following the transaction, the director now directly owns 105,583 shares in the company, valued at $4,064,945.50. The trade was a 48.64% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Genetic Disorder L.P. Kkr sold 6,000,000 shares of the stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $32.96, for a total transaction of $197,760,000.00. Following the transaction, the insider now directly owns 19,260,971 shares of the company's stock, valued at $634,841,604.16. This represents a 23.75% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 12,475,682 shares of company stock worth $419,721,156 in the last 90 days. Insiders own 18.20% of the company's stock.

BridgeBio Pharma Price Performance

Shares of BBIO stock traded up $0.37 on Monday, hitting $33.34. The stock had a trading volume of 2,047,183 shares, compared to its average volume of 2,445,094. The business has a 50 day moving average of $34.50 and a 200 day moving average of $31.92. The stock has a market cap of $6.33 billion, a price-to-earnings ratio of -11.70 and a beta of 1.15. BridgeBio Pharma, Inc. has a 12-month low of $21.62 and a 12-month high of $39.54.

BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) last issued its quarterly earnings data on Tuesday, April 29th. The company reported ($0.88) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.00) by $0.12. The firm had revenue of $36.74 million during the quarter, compared to the consensus estimate of $57.14 million. The company's revenue for the quarter was down 44.8% on a year-over-year basis. During the same period in the previous year, the company posted ($0.20) earnings per share. As a group, research analysts expect that BridgeBio Pharma, Inc. will post -3.67 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages have issued reports on BBIO. JPMorgan Chase & Co. increased their price target on BridgeBio Pharma from $44.00 to $50.00 and gave the stock an "overweight" rating in a report on Monday, March 24th. UBS Group increased their target price on BridgeBio Pharma from $65.00 to $72.00 and gave the stock a "buy" rating in a report on Wednesday, April 30th. Scotiabank boosted their price target on shares of BridgeBio Pharma from $52.00 to $55.00 and gave the company a "sector outperform" rating in a research note on Wednesday, April 30th. Piper Sandler upped their price objective on shares of BridgeBio Pharma from $46.00 to $63.00 and gave the stock an "overweight" rating in a report on Wednesday, April 30th. Finally, Citigroup lifted their price objective on shares of BridgeBio Pharma from $45.00 to $49.00 and gave the company a "buy" rating in a report on Friday, February 21st. One equities research analyst has rated the stock with a hold rating and eleven have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $57.09.

BridgeBio Pharma Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.